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Available online 6 February 2016Leishmaniasis is a neglected disease in tropical countries. Clinical and laboratory features may mimic auto-
immune diseases and this can complicate the Leishmania diagnosis. Due to our previous investigation for false
anti-CCP2 reactivity in Leishmania-infected subjects and our interest in immunity against the joint-speciﬁc colla-
gen type II (CII) in rheumatoid arthritis (RA) we investigated the same cohort for anti-CII antibodies.
We found elevated anti-CII reactivity in Leishmania-infected patients as compared to controls. When anti-CII OD
valueswere comparedwith BSA-blocked control plateswe found higher reactivity against BSA than in CII-coated
plates in many Leishmania-infected patients. The percentage of such false positive anti-CII reactions increased
with inﬂammatory activity, andwas found in almost all Leishmania patientswith highly active inﬂammatory dis-
ease, but was as low in Sudanese healthy controls as well as among Swedish RA patients. The correlation coefﬁ-
cients between false positive anti-CII and anti-CCP2measuredwith a commercial ELISAwere highest for patients
with the most inﬂammatory disease but non-signiﬁcant for Sudanese controls and Swedish RA patients, arguing
that our ﬁndings may have general implications for ELISA measurements in leishmaniasis.
ELISA investigations in areas endemic for leishmaniasis might beneﬁt from individual-speciﬁc control wells for
each serum sample. This approach might also be applicable to other geographical areas or patient groups with
high incidence of inﬂammatory and infectious diseases.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Leishmaniasis is a major public health problem in tropical and sub-
tropical countries. It is endemic in 64 countries, and 90% of the world's
cases are reported in India, Bangladesh, Nepal, Sudan, and Brazil. The
disease may be asymptomatic or subclinical, or may cause a severe
disease called visceral leishmaniasis (VL) or kala-azar. Post-kala-azar
dermal leishmaniasis (PKDL) is a complication of VL characterized by
severe rashes and skin lesions in mostly young patients who have re-
covered from VL (Elshaﬁe et al., 2007).
Leishmania-infected patients can show clinical and laboratory
features that mimic autoimmune hepatitis, primary biliary cirrhosis
and systemic lupus erythematosus (SLE) and wrongly diagnosed as
having such diseases (Sakkas et al., 2008), and like rheumatic diseases
Leishmania-infected patients have high levels of circulating immune
complexes (CIC) and autoantibodies like rheumatoid factor and anti-
nuclear antibodies (ANA) (Elshaﬁe et al., 2007; Sakkas et al., 2008;
Åhlin et al., 2015). We also recently described that Leishmanialogy, Genetics and Pathology,
la, Sweden.
. This is an open access article underdonovani-infected subjects can present with positive reactions against
cyclic citrullinated peptide 2 (anti-CCP2), an autoantibody otherwise
highly speciﬁc for rheumatoid arthritis (RA). The anti-CCP2 reactivity
was in the lowpositive range, in contrast to Sudanese anti-CCP2 positive
RA patients who presentedwith very high anti-CCP2 levels (Åhlin et al.,
2015), in agreement with previous ﬁndings in Caucasian RA patients.
Anti-CCP2 antibodies react with citrulline residues in proteins or pep-
tides where arginine residues have been post-translationally modiﬁed,
and when we compared the anti-CCP2 reactivities with parallel plates
coated with identical peptides except that the citrulline residues had
been exchanged with the native arginine residues we found that the
Leishmania-infected patients reacted equally well with both plates,
whereas the Sudanese RA patient showed citrulline-speciﬁc reactivity.
We concluded that the Leishmania-infected patients reacted in the
anti-CCP2 test in a way that was independent of citrullination of the
peptides (Åhlin et al., 2015).
In this report we present further investigations in RA-associated
autoantibodies in L donovani-infected subjects. Due to our interest in
immunity against the joint-speciﬁc protein collagen type II (CII) in RA
(Mullazehi et al., 2007, 2012) we investigated anti-CII antibodies in
Sudanese subjects. As we found elevated anti-CII reactivity in Leishman-
ia-infected patients as compared to controls, we again performedthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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activity in the control plates than in CII-coated plates. Intriguingly, al-
most all patients with highly active leishmaniasis showed such false
reactivity. As our control plates in this recent experiment were only
blocked, our results raise general concerns about ELISA measurement
of autoantibodies in tropical Africa and perhaps also elsewhere where
Leishmania infection or other highly inﬂammatory infections appear.
2. Methods
2.1. Study subjects
The study was carried out at Tabarakalla rural hospital in Gedarif
state in Northern Sudan, which it is endemic for L. donovani, and
where the main Leishmania vector is Phlebotomaus orientalis (Elshaﬁe
et al., 2007). A detailed clinical history and examination were obtained
from each studied patient. Subjects were questioned about their ethnic,
and geographic origin and were examined for clinical manifestations of
VL and PKDL. A general clinical examinationwas conductedwith partic-
ular reference to hepatomegaly, splenomegaly and lymphnode involve-
ments. All suspected patients were investigated for malaria; those with
malaria infection were excluded. For diagnosis an inguinal lymph node
aspiration was performed on those clinically suspected of having VL
(i.e., all individuals with any of the following clinical ﬁndings: fever for
N2months, left upper quadrant pain, lymphadenopathy, splenomegaly,
or wasting). All individuals with clinically suspected VL but with
negative results on inguinal lymph node aspiration were subjected
to bone marrow aspiration aiming to seek for L. donovani bodies
for VL conﬁrmation.
Leishmania-infected patients included 62 VL patients (20 females
and 42 males; age median (mean): 24 (26) years; range 3–73), 44
PKDL patients (13 females and 31 males; age 23 (20) years; range
3–27) and 49 healthy controls without any disease complaints from
Tabarakalla village (26 females and 23 males; age 22 (20) years; range
3–45). Severely ill patients with VL admitted to the Tabarakalla hospital
for hospitalization were classiﬁed as acute VL (n= 15). Patients not se-
verely ill and treated as outpatients with daily injections of sodium
stibogluconate were classiﬁed as sub-acute VL (n = 47).
Venous blood drawn from patients and healthy controls was
separated by centrifugation and frozen in liquid nitrogen within 2 h of
sampling and transported frozen in liquid nitrogen until analyzed in
Uppsala. Data on 274 Swedish early RA patient sampled at the time of
diagnosis that was made within 1 year after ﬁrst symptoms, as previ-
ously described (Mullazehi et al., 2007) and using exactly the same
anti-CII ELISA are included for comparison.
Ethical approval for this study was obtained from the ethical com-
mittee from the Ministry of Health in Khartoum and Gedarif State,
Sudan. Informed consent was obtained from all the adults who partici-
pated in the study. For younger children, consent was obtained from
their parents. For the Swedish RA patients the ethical approval was ob-
tained from the Ethical Committee at Karolinska Institutet, Stockholm.
Ethical approval to conduct immune complex and autoantibody studies
has also been obtained from the Ethical Board in Uppsala.
2.2. Anti-CII ELISA
The indirect ELISA was performed as in our previous publications
(Mullazehi et al., 2007, 2012). High-binding ELISA plates (Nunc
MaxiSorp, Nunc, Roskilde, Denmark) were coated with human native
CII (Chondrex, Redmond, WA) at a concentration of 5 μg/ml in PBS at
4 °C overnight. Preliminary titrations had showed CII concentrations at
or above 2.5 μg/ml to yield optimal results. The coating solution was
thereafter discarded and the plate blocked with 1% IgG-depleted ELISA
grade bovine serum albumin (Sigma, Stockholm, Sweden) in PBS
(PBS-BSA); for 1 h at room temperature on a shaker. After washing
with PBS+ 0.05% Tween, serum samples (1:101 dilution) and a standardcurve derived from an RA serum with very high anti-CII levels diluted in
PBS-BSA were added to the plates for 2 h at room temperature. After fur-
ther washing, an alkaline phosphatase-conjugated goat anti-human γ
chain speciﬁc antibody (dilution 1:10,000; Jackson ImmunoResearch,
Cambridgeshire, UK)was added at room temperature for 1 h on a shaker.
To minimize unwanted interactions, the antibody used was F(ab′)2 and
had been adsorbed to exhibit minimal crossreactivity with bovine immu-
noglobulins that might remain in the blocking solution. After three more
washings with PBS-BSA the reaction was developed using 4-nitrophenyl
phosphate disodium tablets (Sigma) in diethanolamine buffer and theop-
tical density read at 405nmafter 60min. The cutoff 29U/mlwas set at the
95th percentile among 100 Swedish healthy blood donors as in previous
studies (Mullazehi et al., 2007). Two internal controls were run on all
ELISAplates in parallel to unknown samples, and only plateswith internal
control values within a predetermined range were accepted. The internal
control close to the cutoff had an intra-assay CV of 15%.
Patients with positive reactions were investigated a second time
with comparison of ODvalues in CII coated/BSA blockedwells in parallel
to wells only blocked with BSA in duplicates and on the same plate. We
classiﬁed sampleswithhigher OD in the CII-coatedwells as compared to
the BSA coated wells as true positive and those with the highest OD in
the wells containing only BSA as false positive. Sera with anti-CII levels
below the cutoff 29 AU/ml were denoted as negative and were not fur-
ther investigatedwith parallel BSAwells. This approach is in agreement
with our previous use of the ELISA (Mullazehi et al., 2007, 2012).
2.3. Anti-CCP2 and anti-C1q-binding CIC ELISA measurements
Anti-CCP2 was measured using the Immunoscan RA Mark 2 assay
(Euro-Diagnostica, Malmö, Sweden). In accordance with
manufacturer's instructions 25 U/ml was used as a cut-off. The kit pro-
vides no standard points below 25 U/ml, and the ELISA standard curve
was extended by serial dilution down to 3.13 AU/ml to yield quantita-
tive data also in the low range. C1q-binding CIC were measured with
ELISA as previously described (Åhlin et al., 2015).
2.4. Statistics
Analyses with the Shapiro–Wilk W test and probability (QQ) plots
showed non-normal distribution of anti-CII levels among Sudanese
controls, PKDL and VL patients, both for all data, as well as after exclusion
of true anti-CII positive results. As we previously have shown anti-CII to
be non-normally distributed also in RA patients (Mullazehi et al., 2012)
we used non-parametric tests. For the comparison between two groups,
we used the non-parametric Mann–Whitney's U test for unpaired sam-
ples. To estimate correlations between variables, we used the Spearman
non-parametric test. p values b 0.05 were regarded as signiﬁcant. All cal-
culations were made by means of the software JMP 11 for Mac.
3. Results
3.1. High anti-CII levels in Leishmania-infected patients
Themedian (mean) anti-CII levels among the Sudanese healthy con-
trols were 16 (21) AU/ml. For the PKDL and VL patients the correspond-
ing ﬁgures were 28(43) and 48(58) AU/ml, respectively (Fig. 1). Levels
were signiﬁcantly higher among PKDL (p = 0.0004) and VL (p b 0001)
patients as compared to Sudanese healthy controls. Using the cutoff pre-
viously deﬁned for Sweden, 26% (13/49) of the Sudanese controls, 48%
(21/44) of the PKDL patients and 65% (40/62) of the VL patients showed
reactivity against anti-CII (Fig. 2).
Themedian (mean) values for Swedish RA patients was 12(55), and
10% (27/274) showed anti-CII reactivity. As previously described
(Mullazehi et al., 2012) a small outlier subgroup of the Swedish RA
patients showed very high levels of CII (9/274) patients with levels be-
tween 470 and 3522) not seen on our Leishmania cohort. The
Fig. 1.Anti-CII levels among the Sudanese and the Swedish subjects. The lower dashed horizontal line represents the 95th percentile cutoff value previously calculated for Swedish patients
(29 AU/ml), the upper dashed horizontal line represents the 95th percentile calculated from Sudanese healthy controls and the solid lines represent themedian levels of anti-CII for each
group. All data are shown, and subdivided into negative (ﬁlled circles), true positive reactions with higher OD in CII wells than in BSA wells (triangles) and false positive reactions with
higher OD in BSA wells than in CII wells (stars).
68 A.I. Elshaﬁe et al. / Journal of Immunological Methods 431 (2016) 66–71proportions of CII positivity were also higher in subjects with Leishman-
ia infection when compared to the Swedish RA patients (p b 0001 com-
pared to both PKDL and VL patients; Fig. 1).
3.2. Leishmaniasis patients, especially acutely ill VL patients, exhibit false
positive anti-CII reactivity in ELISA
After further evaluation of the anti-CII positive subjects with only
blocked control plates we found that the majority of anti-CII positive
Leishmania-infected subjects exhibited false positive reactivity. False
positive anti-CII reactivity increased with increasing inﬂammatory ac-
tivity in a stepladder fashion from Sudanese healthy controls to PKDL
via subacute VL and ﬁnally to acute VL where almost all subjects 93%
(14/15) show a false positive anti-CII reactivity. Among the Swedish
RA patients 1.5% (4/274) exhibited false positive anti-CII reactivity,
very similar to the Sudanese control subjects 2% (1/49). The distri-
butions of negative, true positive and false positive anti-CII reactivity
in the investigated groups using the Swedish cutoff are graphically
depicted in Figs. 1 and 2. Also when using a higher cut-off based on
the 95th percentile among the Sudanese controls (80.4 U/ml) we get a
parallel relative increase in false reactivity when we move from
Sudanese healthy controls (0/49, 0%) to PKDL (2/44, 4.5%), subacute
VL (8/47, 17%) and acute VL (8/15, 53%; data not shown).
3.3. Non-related ELISA results correlate strongly in visceral leishmaniasis
patients
To investigatewhether the high degree of false positive anti-CII reac-
tions especially in the VL group might be a universal ﬁnding in ELISA
tests, we studied the correlation between the commercial ELISA in the
different groups. As we hypothesized that especially false positive reac-
tivities might show a high degree of correlation among patients withhigh inﬂammatory activity we ﬁrst calculated correlation without ex-
cluding subjects with true positive results and thereafter re-calculated
this correlation only for subjects with negative or false positive anti-
CII results as shown in Fig. 3. The correlation coefﬁcients increased
after exclusion of true positive reactions for both Leishmania-
infected groups, and the largest correlation coefﬁcient was found
for VL patients. Thus the false anti-CII reactivity showed the stron-
gest correlation to results obtained from an unrelated commercial
ELISA for VL patients, the group with the highest percentage of
false positive anti-CII reactions, and the correlation coefﬁcients in-
creased when true positive anti-CII reactions had been excluded in
PKDL and VL patients, both groups with inﬂammatory disease. For
subjects not infected with Leishmania, Sudanese healthy controls
and Swedish RA patients, there was no signiﬁcant correlation be-
tween anti-CCP2 and anti-CII after exclusion of true positives. For
the Sudanese subjects, this comparison could only be made for
anti-CCP2 variation below the cutoff, as sera from the (false) anti-
CCP2 positive Leishmania-infected subjects had been exhausted in
the experiments described in (Åhlin et al., 2015).
3.4. No correlation between circulating immune complexes and false
positive anti-CII reactivities among Leishmania-infected patients
As CIC levels are increased in Leishmania patients, and as CIC might
be a cause of false positive reactions in ELISAwe correlated CIC and anti-
CII levels after exclusion of true positive anti-CII samples. For all
Sudanese subjects (healthy controls, PKDL and VL patients) there was
a signiﬁcant correlation (r = 0.53, p b 0.0001, n = 123), whereas no
signiﬁcant correlation was seen for any of the groups investigated indi-
vidually (controls: r= 0.26, p=0.12, n=37; PKDL: r= 0.36, p=0.30,
n = 35; all VL subjects: r = 0.26, p = 0.071, n = 51; subacute VL: r =
0.14, p=0.36, n=36, acute VL: r=0.37, p=0.22, n=15). Due to lack
Fig. 2. Proportions of negative, true positive and false positive anti-CII reactivities among the Sudanese and Swedish subjects. Reference range for positive reactivity is based on the cutoff
based on the 95th percentile among Swedish healthy controls.
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levels.
4. Discussion
In a previous report we deﬁned that Leishmania-infected subjects
from an endemic area in Sudan possess a false positive anti-CCP2 reac-
tivities in ELISA, as the patients reacted equally well against ELISAwells
with citrullinated peptides or with arginine-containing control peptides
(Åhlin et al., 2015). In the current studywe extend these studies to anti-
CII, another RA-associated autoantibody. Also here Leishmania-infected
patients react stronger to control wells. But as the control wells in our
current study only are blocked with the same blocking agent as used
in the CII-coated wells and this blocking solution is common to many
widely used ELISA protocols, the ﬁndings might be valid for any ELISA
using a simple blocking system, and raises general concerns about the
detection of antibodies with ELISA in Leishmania-infected subjects and
possibly also in other diseases with high inﬂammatory activity. Both
in our previous report (Åhlin et al., 2015) and in our current study
(Fig. 1), the false ELISA reactivities found in Leishmania-infected patients
are found in the low positive range, whereas positive control groups
with RA patients show strong and true positive reactions against anti-
CCP2 and anti-CII, respectively. The ﬁndings might be applicable also
to commercial ELISA systems as we show a high degree of correlation
between anti-CCP2 and anti-CII especially in patients with VL, the
most inﬂammatory form of leishmaniasis. None of the autoantibodiesanti-CCP2 or anti-CII have any known association to Leishmania infec-
tion, and when we exclude the low number of true anti-CII positive
reactivities and thus focus on the false reactive patients, the signiﬁcant
correlation between the two unrelated autoantibodies increase in both
groups of Leishmania-infected patients. On the contrary, there is no
such correlation between false anti-CII reactivity and anti-CCP2 in the
control groups of Sudanese healthy individuals or Swedish RA patients.
In fact, anti-CII and anti-CCP2 represent two clinically distinct pheno-
types when investigated in the same RA cohort (Mullazehi et al.,
2007; Rönnelid et al., 2005).
In our previous paper, the false positive anti-CCP2 reactivity was
only marginally diminished after depletion of immune complexes
(Åhlin et al., 2015), but we did not have enough samples left for parallel
investigations for anti-CII. We anyhow think that the false anti-CII reac-
tivity determined in Leishmania-infected subjects is probably not relat-
ed to immune complexes, as none of the Sudanese subgroups showed
any correlation between CIC and false anti-CII reactivity when analyzed
separately. The fact that these variables correlated when all Sudanese
subjects were analyzed together is probably a group effect. Both mea-
sures are increased in Leishmania infected patients as compared to in
Sudanese controls, as we have shown previously for CIC (Åhlin et al.,
2015) and in this paper for false positive anti-CII reactivity.
Our ﬁndings should be considered when handling the diagnostics of
Leishmania-infected subjects in tropical areas like Sudan. Previous re-
ports and our own experience (AE) state that the clinical presentation
of Leishmania infection can be misclassiﬁed as autoimmune diseases
Fig. 3. Correlation between anti-CII and anti-CCP2 levels for a.) Sudanese healthy controls, b.) PKDL patients, c.) VL patients and d.) Swedish RA patients. The correlation coefﬁcients rs and
signiﬁcance levels were calculated with the Spearman rank correlation test. Correlation data for all subjects are shown before the slash signs, and after exclusion of subjects with true
positive anti-CII after the slash signs. Filled circles represent negative and true positive results for CII and stars represent false positive reactions with higher OD in BSA wells than in CII
wells. Fifteen Swedish RA patients with very high anti-CCP2 or anti-CII levels are not shown in d.) but included in the statistical calculations.
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nuclear antibodies (ANA), IgM rheumatoid factor, anti-DNA and anti-
cardiolipin (Sakkas et al., 2008). In that clinical setting physicians
might request autoantibody testing by ELISA to conﬁrm the clinical sus-
picion of autoimmunity. If the requested ELISA present the kind of gen-
eral false reactivity described in this report, misdiagnosis and wrong
management in subjects infected with L. donovani infection may ensue.
Also previous papers have reported false ELSA antibody reactivity in
tropical and developing areas, concerning malaria serology (Ghosh
et al., 2001), anti-neutrophil cytoplasmic antibodies (ANCA) (Ghosh
et al., 2008) and Chlamydia serology (Miyashita et al., 2008). In our
paper we extend these ﬁndings to encompass two independent ELISA
systems for measurement of autoantibodies not related to Leishmania-
infected patients. We show that there is a strong correlation between
the reactivities measured with these two ELISAs, especially when the
few true anti-CII positive samples had been excluded, and thus that
the ﬁnding of false reactivity is not dependent on speciﬁc autoantibody
reactivities, but on the ELISA format per se.
Before performing this study we only had access to Swedish anti-CII
data, and the deﬁnition of which samples should be subjected to a
second round of comparison with only blocked wells was based on
the reference range derived from Swedish controls. As the general
anti-CII levels among healthy controls living in the Sudanese village ofTabarakalla turned out to be higher than among Swedish blood donors,
we have calculated a second cutoff derived from Sudanese controls, and
thereby we have deﬁned individuals between the two cutoff lines as ei-
ther true or false positive (Fig. 1). In this purely technical report
including individuals from both countries we have chosen to keep the
deﬁnition of positivity based on Swedish data, but as we describe in
Section 3.2, the general ﬁndings are the same using a cutoff based on
Tabarakalla controls (Figs. 1 and 2). In a clinically oriented paper, one
should of course always interpret autoantibody data in relation to a con-
trol population that is clinically relevant to the study in question.
In our view, indirect ELISA or other solid phase immune assay tests
for antibodies to be used in areaswith Leishmania infectionmight be ac-
companied by simultaneous evaluation of reactivity in control wells
without the target antigen. This is not currently the case, see e.g.
(Abass et al., 2013). Very few commercial solid phase antibody systems
use such individual control wells, to our knowledge the only exception
being the anti-SA test for a subgroup of anti-citrullinated protein/pep-
tide antibodies (ACPA) delivered by the company Euroimmun. An obvi-
ous drawback of this approach suggested by us is that the number of
samples to be tested in each ELISA plate is diminished by 50% as haft
of the ELISA plates will be used for control wells.
As other reports have shown false reactivity in ELISA tests also in
other tropical diseases (Ghosh et al., 2001, 2008; Miyashita et al.,
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extended to other infectious disease settings and also to other conti-
nents than Africa. One example is the false positive anti-CCP2 reactivity
in hepatitis C-infected subjects in USA where the authors used only
blocked ELISA plates as individual controls and reported that the bind-
ing was caused by nonspeciﬁc binding to plastic (Wener et al., 2004).
The ﬁndings might not be limited to indirect antibody ELISA systems,
as nonspeciﬁc binding to the matrix including e.g. blocking agent and
plastic might appear also in direct ELISA and sandwich ELISA systems.
These hypotheses need validation in further studies.
5. Conclusion
Our data imply that sera from Leishmania-infected subjects often react
non-speciﬁcally in ELISA andwe therefore suggest that individual-speciﬁc
control wells should be included for antibody measurements in areas
endemic for leishmaniasis. These suggestions might also be applicable
to other geographical areas or patients groups with high incidence of
inﬂammatory and infectious diseases.
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